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Abstract 
Poorly differentiated thyroid carcinoma (PDTC) was originally described in 1983 but 
included in the WHO classification of thyroid tumors in the 2004 edition, only. The diagnostic 
problems encountered in these five years of application of the WHO criteria are here reviewed. 
A long debate is still going on the nature of PDTC, its morphological diagnostic features, its 
clinical significance and its optimal therapeutic approach. A consensus conference held in Turin 
in 2006 confirmed the geographical differences among claimed classical forms of PDTC and 
suggested a diagnostic algorithm based on the presence of a solid/trabecular/insular growth 
pattern and of high grade features, in line with the WHO definition of PDTC, capable to select 
tumors with a distinct aggressive clinical behaviour. This worked well for PDTC cases from 
mountain areas (e.g. Northern Italy), where most, if not all, thyroid carcinomas having high 
grade features also share a solid/trabecular/insular pattern of growth. However, this scheme 
might be less easily applicable for American and Japanese cases, possibly due to heterogeneous 
architectural and cytological features; indeed some Authors still prefer to base their diagnostic 
work up on the recognition of high grade features only, including mitotic index and necrosis, 
irrespective of the growth pattern.  
 
 
 
Keywords: poorly differentiated carcinoma, thyroid, diagnosis 
 
 
  4 
Foreword 
Since the original description of poorly differentiated thyroid carcinoma (PDTC) in 1983 
[1], a long debate has occurred on the very nature of this tumor, on its morphological diagnostic 
features, on its molecular profile and on its clinical significance [2-10]. PDTC was defined as a 
thyroglobulin-producing non-follicular non-papillary thyroid carcinoma, having an intermediate 
behaviour between well differentiated and anaplastic carcinomas. In the 2004 WHO 
Classification of Endocrine Tumors [11], PDTC was introduced as a separate entity, and its 
recognition was based on both architectural (non-follicular/non-papillary growth pattern) and 
high-grade features (invasive growth, high mitotic index and necrosis).  
After five years, the above mentioned proposed criteria are still controversial and 
heterogeneously applied in the diagnostic practice. Therefore, some overlap exists with other 
tumor categories, including the solid variant and the tall cell variant of papillary carcinoma on 
the one side and follicular carcinomas with predominant solid/trabecular growth patterns on the 
other (Figure 1). As a result, the term PDTC encompasses a remarkably heterogeneous group of 
tumors only partially related, thus preventing a reproducible and well defined diagnostic 
approach (Table 1) and, perhaps, an appropriate clinical management. Such heterogeneity 
became dramatically evident at a consensus meeting held in Turin in 2006, in which allegedly 
clear cut examples of PDTC collected from different countries (indeed continents) were 
reviewed and discussed (see below).  
 
Established facts 
 With regard to PDTC diagnosis, some issues seem relatively well-defined. These include: 
1) PDTC displays predominant solid/trabecular/insular growth patterns which may coexist 
with more or less extensive differentiated components of the follicular or papillary type on the 
one side, and of the anaplastic carcinoma type on the other. While this latter event is extremely 
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rare, representing less than 1% of cases at least in our series from a mountain area of Northern 
Italy, the former is more common; however, such combination does not seem to affect PDTC 
prognosis, which is generally driven by the poorly differentiated component and is worse than 
that of the corresponding conventional follicular or papillary carcinomas.  
2) PDTC having predominant oncocytic changes (oxyphilic, Hurthle cell) are not a separate 
entity, but a variant of PDTC. In fact, the current WHO classification of thyroid tumors [11] has 
incorporated oncocytic tumors as variants of the conventional follicular-derived neoplastic 
subtypes, including PDTC. The presence of mitochondrion-rich cells and/or oncocytic changes 
can be recorded in the pathology report, but is not a relevant diagnostic or prognostic feature 
requiring a different tumor categorisation [12, 13].  
3) The immunohistochemical profile of PDTC is that of a follicular-derived tumor, 
including thyroglobulin production (generally, in intracellular paranuclear vacuoles) and TTF-1 
expression. PDTC was labelled as “poorly differentiated” based on the assumption that lack of 
follicles was a synonym of loss of normal thyroid structure (indeed conventional papillary cancer 
also lacks follicles, but is nevertheless a well differentiated thyroid tumor). However, from a 
functional or endocrine point of view, the majority of PDTC maintain their capacity to produce 
hormones, and thyroglobulin is an important immunohistochemical marker for the differential 
diagnosis of PDTC from other trabecular lesions of the thyroid gland [14], as well as a useful 
post-operative serum marker in the patient‟s follow up. Markers of malignancy in follicular 
tumors (such as HBME-1, galectin-3, etc) may also be expressed in PDTC, but have no practical 
diagnostic application, since morphological signs of malignancy (i.e. vascular invasion) are 
unequivocally present in all cases.  
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Open questions  
From the publication of the WHO classification of Tumors of Endocrine Organs [11] five  
years ago, a large debate was generated on PDTC morphological and clinical features, which is 
still ongoing worldwide. Some issues, among others, will be briefly commented on, with special 
reference to the most recently published studies on the matter.     
1) Mitoses and necrosis vs growth pattern. Several studies based on large case series 
identified high mitotic index and presence of necrosis as relevant parameters associated to 
adverse prognosis in thyroid cancer, and therefore considered them a distinctive hallmark of 
PDTC [13, 15]. Indeed, such high grade features were considered by some of these Authors the 
only relevant ones for PDTC definition [15], irrespective of the growth pattern. As a 
consequence, in the PDTC group, aggressive variants of well differentiated carcinomas were 
also included, such as the tall cell variant of papillary carcinoma (indeed having distinct 
pathological features and clinical behaviour, compared to PDTC) [16, 17]. On the other side, the 
presence of a predominant insular component was demonstrated to be associated per se to a 
more aggressive behaviour, even in recent papers [18]. Recently, the “Turin proposal” 
summarized the results of  a consensus conference that involved 12 pathologists from Japan, United 
States and Europe, and suggested a diagnostic algorithm for PDTC diagnosis [19, 20]. According to 
such algorithm, a PDTC is defined by the following diagnostic criteria: i) presence of a 
solid/trabecular/insular pattern of growth in an otherwise malignant thyroid lesion (to an extent not 
clearly settled: „„the majority of the tumor‟‟ is mentioned as a requirement in the WHO book); ii) 
absence of the conventional nuclear features of papillary carcinoma, to distinguish PDTC from the 
solid variant of papillary carcinoma, which is characterized by a solid/trabecular growth pattern, but 
bears a significantly better prognosis than PDTC in the adult population [21]; iii) presence of 
convoluted nuclei or mitotic activity >3x10 HPF or tumor necrosis (at least one feature). Convoluted 
nuclei are smaller and darker than papillary carcinoma nuclei, and are round, hyperchromatic with 
convolutions of the nuclear membrane („„raisin-like‟‟ contours). A recent Japanese study [22] aimed 
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at investigating the prevalence and clinical significance of „„three types of poorly differentiated 
carcinoma‟‟ - as defined by Sakamoto [1], WHO classification [11]  and the Turin proposal [19] - as 
well as of the tall cell variant of papillary carcinoma; this study  confirmed that different tumor 
groups are identified by the different inclusion criteria and showed that significant differences among 
the groups were also present in terms of survival, being cases identified according to the Turin 
proposal those associated to the worst survival rates. 
2) Prognostic factors in PDTC. It is widely shared that PDTCs have a distinct and 
intermediate prognosis within the spectrum of follicular-derived thyroid cancers [16]. However, 
prognostic stratification of PDTC patients is largely biased by the extensive overlap existing 
between “diagnostic” and “prognostic” parameters. As an example, the presence of a high 
mitotic index and/or necrosis has been alternatively considered a diagnostic hallmark of PDTC 
or a negative prognostic indicator. As a consequence, several parameters have variably been 
proposed to be associated to a worse prognosis in PDTC, but very few have been confirmed in 
additional studies and by means of appropriate statistical (multivariate) analysis. Running 
through the most recent studies applying the WHO classification, age 45 or higher, high TNM 
stage, extrathyroidal extension, presence of distant metastases and no post-operative radioiodine 
therapy administration (indeed the most relevant parameter at multivariate analysis) have been 
associated to a more aggressive clinical course in PDTC [17, 23].  
3) Radioiodine uptake. From a clinical perspective, the immunohistochemical profile of 
thyroglobulin production is reflected by the ability of radioiodine uptake displayed by the 
majority of PDTC (up to 80% of cases), both in the primary tumors and in distant metastases [8, 
13, 15, 23, 24]. In our and other Authors‟ experience, radioiodine uptake by the tumor is 
associated to successful 
131
I radiotherapy [8, 17, 23], although this view is not shared by other 
Authors [25, 26], possibly reflecting geographical differences in terms of different tumor stages 
at the time of radioiodine treatment and/or different timing and dosage of radioactive iodine 
administration. However, standard postoperative dosages of 
131
I  do not differ from those of well 
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differentiated thyroid cancer [17, 23]. It is worth noticing that recently a high prevalence of 
PDTC histotype was found in a series of radioiodine refractory metastatic thyroid cancers, and 
that, in this specific subgroup of patients, the presence of necrosis and extrathyroidal extension 
were associated to shorter disease-specific survival [27]. 
4) PDTC-specific molecular signatures? Several molecular alterations have been 
investigated to define PDTC histogenesis, but the molecular genetic data so far reported in the 
literature reflect the heterogeneity of the case series analyzed, as the result of the discrepancies in 
PDTC diagnosis and classification. Generally, irrespective of the selection criteria applied, RAS 
point mutations appear to be a common molecular alteration in these tumors, although they were 
found with highly variable frequency and wide variation in specific types of RAS mutations [4, 
28, 29]. Likewise, BRAF mutations were detected in poorly differentiated carcinomas having 
residual papillary carcinoma foci [30, 31], but not in cases lacking the morphologic evidence of 
transition from well differentiated papillary to poorly differentiated carcinoma [32]. 
Interestingly, in a recent study, BRAF mutations have been associated to FDG-PET--positive 
radioiodine refractory thyroid cancers [33]. RET/PTC1 rearrangements were found in a fraction of 
poorly differentiated carcinomas having the nuclear features of papillary carcinoma and/or some 
(residual) foci of papillary carcinoma [34]. The occurrence of β-catenin mutations in PDTC is 
controversial, ranging from 0% [35] to 32% [36] of tumors in two different studies.  Finally, 
TP53 mutations were described in a subset of PDTC by different authors [37, 38], and proposed 
as a molecular marker of thyroid tumor de-differentiation and progression. 
 
 
Conclusions 
 PDTC still represent a challenging issue for both pathologists and clinicians. Their 
classification into a separate group by the WHO is justified by their biological and clinical 
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behaviour - intermediate between well differentiated and anaplastic thyroid cancers, but they are 
affected by a still equivocal diagnostic approach  and by an incompletely standardized therapy. A 
certain degree of confusion depends on the overlap between diagnostic and prognostic 
parameters in PDTC (e.g. vascular invasion, growth pattern, mitotic index, necrosis, and others), 
thus making a strict prognostic stratification of PDTC patients difficult, and subsequently a well-
defined therapeutic approach poorly achievable. Molecular data are controversial and limited by 
the heterogeneous case series analyzed, and should be re-defined in strictly re-classified PDTC 
and devoted to both understanding the histogenesis of PDTC and identifying novel prognostic 
and predictive markers in this type of aggressive thyroid tumors.  
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Table 1. Established facts and controversial issues onto poorly differentiated thyroid carcinoma. 
Established fact Comment Controversy 
Solid/trabecular/ 
insular growth pattern 
should be predominant 
Growth pattern recognition is a keystone for PDTC 
recognition, although it is not unique of this tumor 
entity [11] 
 
Follicular, papillary 
and anaplastic 
carcinoma components 
may be associated 
The presence of an associated component defines a 
subset of PDTC (i.e. so called „„papillary type‟‟ [19]) 
but, except for the association with anaplastic 
carcinoma, bears no clinical implication 
 
The presence of 
predominant oncocytic 
features defines the 
oncocytic variant of 
PDTC 
PDTC with predominant oncocytic features behave 
as the „„conventional‟‟ type [12]; they share with other 
oncocytic thyroid tumors common morphological 
features but their immunophenotypical and molecular 
profile is yet unexploited  
 
Follicular derivation is 
proven by 
thyroglobulin and TTF-
1 positive IHC  
The role of immunohistochemistry in PDTC diagnosis 
is limited to exclusion of other thyroid lesions not 
derived from the follicular epithelium (i.e. medullary 
carcinoma, parathyroid tumors, metastases) [14] 
 
 The presence of necrosis and/or high mitotic count are 
considered diagnostic of PDTC when associated to a 
predominant solid/trabecular/insular growth pattern 
[19]; however, they are considered exclusive 
hallmarks of PDTC by some Authors, irrespective of 
the growth pattern [15]  
High grade features 
are diagnostic of 
PDTC 
 „„Convoluted‟‟ nuclei have been introduced in the Convoluted nuclei 
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Turin proposal as a distinctive feature of a subset of 
PDTC [19]. However their exact histopathogenetic 
meaning and diagnostic reproducibility are poorly 
defined. 
are diagnostic of 
PDTC 
 At multivariate survival analysis age >45 yrs, high 
pTNM stage, extrathyroidal extension, presence of 
distant metastases and no radioiodine therapy 
administration have been associated to worse 
prognosis [17, 23]. The presence of necrosis and high 
mitotic count are known relevant prognostic 
parameters in thyroid tumors, but, since they are 
diagnostic parameters in PDTC, their prognostic role 
is equivocal in this tumor type and prognostic cut off 
threshold (i.e. for mitoses) are to be settled 
Relevant prognostic 
parameters in PD 
carcinoma 
 Up to 80% of PDTC uptake radioiodine, but data on 
the responsiveness rate to radioiodine therapy are 
controversial in the literature [8, 17, 23, 25, 26], and a 
high prevalence of PDTC histotype has been found in 
radioiodine refractory metastatic thyroid cancers [27] 
Is radioiodine 
therapy useful in 
PDTC? 
 RAS gene, namely NRAS, demonstrates the highest 
rate of mutations in PDTC, occurring in 20 to 60% of 
cases [4, 28], whereas BRAF and RET/PTC 
alterations are variably reported in the literature in 
PDTC, according to the different selection criteria 
used 
PDTC molecular 
pathogenesis 
Legend. PDTC: poorly differentiated thyroid carcinoma. IHC: immunohistochemistry. 
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Figure legend 
 
Figure 1. Comparative illustration of typical features of PDTC and some of its mimics.  
“PDTC” column of figures: PDTC is a malignat thyroid tumor with wide vascular invasion 
(top left) and common peritheliomatous necrosis (top right); residual microfollicular architecture 
may be  admixed with predominant solid/trabecular/insular areas (middle left) and a subset of 
cases shows the so-called “convoluted” nuclei (middle right; mitotic figure in the inset);  
predominant oncocytic features in an otherwise PDTC define the oncocytic variant (bottom left; 
necrotic focus at the top of figure); nuclear pleomorphism may be encountered particularly in 
oncocytic areas (bottom right) but does not necessarily imply anaplastic transformation   
“PDTC mimics” column of figures: malignant thyroid tumors that enter in the differential 
diagnosis with PDTC include follicular carcinoma with solid growth (top) that may show 
extensive vascular invasione (top inset) but lacks necrosis or increased mitotic activity, solid 
variant of papillary carcinoma (middle right) that shows the typical papillary carcinoma nuclei 
(middle left) and medullary carcinoma with predominant solid growth (bottom right) lacking 
amyloid stroma (bottom left); in this latter case, thyroglobulin and/or calcitonin 
immunohistochemistry is essential for a correct diagnosis.  
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